
    low accrual rate
  
['metastatic alveolar soft part sarcoma']
['pazopanib']

        Key Inclusion Criteria:

          -  Histologically confirmed diagnosis of alveolar soft part sarcoma harboring TFE3 fusion
             at stage IV or at relapse

          -  Age ≥ 18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Measurable lesion defined by RECIST v1.1

          -  Chemo-naïve or prior chemotherapies

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior malignancies

          -  Active CNS disease

          -  High-risk for gastrointestinal bleeding

          -  Significant cardiovascular disease

          -  Uncontrolled hypertension

          -  Bleeding diathesis
      